The American College of Physicians (ACP) issued new A1C guidelines for people managing type 2 diabetes, drawing both criticism and praise. Here’s what to know about the new target range and what ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

In this study, we demonstrate a case series of three patients with a substantial reduction in A1C and significantly reducing the need for pharmacotherapy without clinically significant weight loss.

Mifepristone reduced A1C by 1.5% as compared to a reduction of 0.2% with placebo. The A1C reductions occurred even as many patients decreased or stopped other diabetes medications, including insulin.

Mifepristone reduced A1C by 1.5% as compared to a reduction of 0.2% with placebo. The A1C reductions occurred even as many patients decreased or stopped other diabetes medications, including insulin.

In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.

In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American ...